247 related articles for article (PubMed ID: 3131451)
1. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
2. [Serum levels of beta 2-microglobulin in monoclonal gammopathies].
Pasqualetti P
Ann Ital Med Int; 1987; 2(1):31-6. PubMed ID: 3152791
[No Abstract] [Full Text] [Related]
3. Pregnancy-specific beta 1-glycoprotein in serum in monoclonal gammopathies: relationship with serum beta 2-microglobulin, and cellular origin.
Fagnart OC; Tasiaux N; Masson PL
Clin Chem; 1986 Dec; 32(12):2150-4. PubMed ID: 3096609
[TBL] [Abstract][Full Text] [Related]
4. Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.
Morell A; Riesen W
Acta Haematol; 1980; 64(2):87-93. PubMed ID: 6159767
[TBL] [Abstract][Full Text] [Related]
5. [Significance of serum beta 2-microglobulin in the differential diagnosis of benign and malignant M-globulinemia].
Wu YF; Zhu JZ
Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):265-6, 313. PubMed ID: 2509168
[TBL] [Abstract][Full Text] [Related]
6. Serum neopterin and beta 2-microglobulin concentrations in monoclonal gammopathies.
Fine JM; Lambin P; Desjobert H
Acta Med Scand; 1988; 224(2):179-82. PubMed ID: 3048055
[TBL] [Abstract][Full Text] [Related]
7. Placental proteins as tumor markers in human monoclonal gammopathies: results in 109 patients.
Morrow JS; Levin DL; Kyle RA; Rosen SW
Tumour Biol; 1985; 6(3):221-32. PubMed ID: 3934736
[TBL] [Abstract][Full Text] [Related]
8. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
9. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
10. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
11. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma.
Boccadoro M; Battaglio S; Omedè P; Palumbo AP; Fusaro A; Frieri R; Gallone G; Polloni R; Mosso R; De Filippi PG
Eur J Haematol; 1991 Oct; 47(4):305-9. PubMed ID: 1954991
[TBL] [Abstract][Full Text] [Related]
12. The monoclonal gammopathies.
Kyle RA
Clin Chem; 1994 Nov; 40(11 Pt 2):2154-61. PubMed ID: 7955402
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of the monoclonal macroglobulinemias].
Corral Corral C; Pérez Peña F; Schüller Pérez A
Rev Clin Esp; 1984 Apr; 173(1):1-7. PubMed ID: 6429750
[No Abstract] [Full Text] [Related]
14. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
15. Serum beta 2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: a clinical study of 55 patients.
Chelazzi G; Senaldi G
Ric Clin Lab; 1986; 16(1):53-8. PubMed ID: 3090677
[TBL] [Abstract][Full Text] [Related]
16. Detection of anti-histone activity in sera of patients with monoclonal gammopathies.
Shoenfeld Y; el-Roeiy A; Ben-Yehuda O; Pick AI
Clin Immunol Immunopathol; 1987 Feb; 42(2):250-8. PubMed ID: 3100119
[TBL] [Abstract][Full Text] [Related]
17. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
20. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
